Overview
- Editors:
-
-
Torgny Stigbrand
-
Department of Immunology, University of Umea, Umea, Sweden
-
Jörgen Carlsson
-
Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
-
Gregory P. Adams
-
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
- Focus on biological effects of targeted radionuclide therapy
- Comprehensive presentation of different mechanisms of tumor cell death
- Up-to-date presentation of new targeting agents
- Summaries of present state of clinical applications of targeted therapy
- Introduction of the new concept; Autosensitization during radionuclide therapy
Access this book
Other ways to access
Table of contents (21 chapters)
-
Front Matter
Pages i-xiii
-
- Jörgen Carlsson, Torgny Stigbrand, Gregory P. Adams
Pages 1-11
-
- Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson
Pages 13-23
-
-
- Torgny Stigbrand, David Eriksson, Katrine Riklund, Lennart Johansson
Pages 59-76
-
-
-
- Marion de Jong, Suzanne M. Verwijnen, Monique de Visser, Dik J. Kwekkeboom, Roelf Valkema, Eric P. Krenning
Pages 117-144
-
-
-
- Øyvind S. Bruland, Dahle Jostein, Dag Rune Olsen, Roy H. Larsen
Pages 181-194
-
- Hans Lundqvist, Bo Stenerlöw, Lars Gedda
Pages 195-214
-
- David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
Pages 215-248
-
- Bo Stenerlöw, Lina Ekerljung, Jörgen Carlsson, Johan Lennartsson
Pages 249-266
-
- David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
Pages 267-284
-
- David Eriksson, Katrine Riklund, Lennart Johansson, Torgny Stigbrand
Pages 285-293
-
-
-
-
- Brian Marples, Sarah A. Krueger, Spencer J. Collis, Michael C. Joiner
Pages 329-347
About this book
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book “Targeted Radionuclide Tumour Therapy – Biological Aspects” was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.
Reviews
From the reviews:
"This book is devoted to understanding the biological aspects of targeted radiotherapy and discusses in depth the various targeting agents as well as the radiopharmaceuticals used in targeted therapy. … Physicians, physicians in training, and physicists who use radionuclide targeted agents in the specialties of radiation oncology, medical oncology, and nuclear medicine are the intended audience. … Overall this is a very informative book for physicians particularly interested in the biological aspects of targeted radiotherapy." (James G. Douglas, Doody’s Review Service, November, 2009)
Editors and Affiliations
-
Department of Immunology, University of Umea, Umea, Sweden
Torgny Stigbrand
-
Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
Jörgen Carlsson
-
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA
Gregory P. Adams
